Literature DB >> 14585075

Guardians of cell death: the Bcl-2 family proteins.

Peter T Daniel1, Klaus Schulze-Osthoff, Claus Belka, Dilek Güner.   

Abstract

Apoptosis is mediated through at least three major pathways that are regulated by (i) the death receptors, (ii) the mitochondria and (iii) the ER (endoplasmic reticulum). In most cells, these pathways are controlled by the Bcl-2 family of proteins that can be divided into anti-apoptotic and pro-apoptotic members. Although the overall amino acid sequence homology between the family members is relatively low, they contain highly conserved domains, referred to as BH (Bcl-2 homology) domains (BH1-4), that are essential for homo- and hetero-complex formation, as well as for their cell-death-inducing capacity. Structural and functional analyses revealed that the pro-apoptotic homologues can be subdivided into the Bax subfamily and the growing BH3-only subfamily. Recent data indicate that BH3-only proteins act as mediators that link various upstream signals, including death receptors and DNA damage signalling, to the mitochondrial and the ER pathway. This review discusses recent structural and functional insights into how these subfamilies promote or inhibit cell-death signals, and how these properties may be utilized for development of apoptosis-promoting small molecules, e.g. in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14585075     DOI: 10.1042/bse0390073

Source DB:  PubMed          Journal:  Essays Biochem        ISSN: 0071-1365            Impact factor:   8.000


  33 in total

1.  Systematic genetic dissection of p14ARF-mediated mitochondrial cell death signaling reveals a key role for p21CDKN1 and the BH3-only protein Puma/bbc3.

Authors:  Philipp G Hemmati; Annika Müer; Bernd Gillissen; Tim Overkamp; Ana Milojkovic; Jana Wendt; Bernd Dörken; Peter T Daniel
Journal:  J Mol Med (Berl)       Date:  2010-04-25       Impact factor: 4.599

Review 2.  Mitochondria: a target for cancer therapy.

Authors:  Jeffrey S Armstrong
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 3.  [Basics of molecular diagnostics and therapy of malignant tumors].

Authors:  P T Daniel; B Dörken
Journal:  Internist (Berl)       Date:  2005-08       Impact factor: 0.743

4.  Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.

Authors:  Bernhard Gillissen; Anja Richter; Antje Richter; Robert Preissner; Klaus Schulze-Osthoff; Frank Essmann; Peter T Daniel
Journal:  J Biol Chem       Date:  2017-02-01       Impact factor: 5.157

5.  Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line.

Authors:  Bin Wu; Qiang Zhang; Weiming Shen; Jun Zhu
Journal:  Mol Cell Biochem       Date:  2008-04-09       Impact factor: 3.396

6.  Mitochondrial Death Channels.

Authors:  Keith A Webster
Journal:  Am Sci       Date:  2009-09       Impact factor: 0.548

7.  Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells.

Authors:  Kumudha Balakrishnan; William G Wierda; Michael J Keating; Varsha Gandhi
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

8.  Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.

Authors:  Bernhard Gillissen; Jana Wendt; Antje Richter; Anja Richter; Annika Müer; Tim Overkamp; Nina Gebhardt; Robert Preissner; Claus Belka; Bernd Dörken; Peter T Daniel
Journal:  J Cell Biol       Date:  2010-03-22       Impact factor: 10.539

9.  Immune-mediated anti-neoplastic effect of intratumoral RSV envelope glycoprotein expression is related to apoptotic death of tumor cells but not to the size of syncytia.

Authors:  Dennis Hoffmann; Thomas Grunwald; Wibke Bayer; Oliver Wildner
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

10.  Expression and function of bcl-2 proteins in melanoma.

Authors:  Jürgen Eberle; Amir M Hossini
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.